nodes	percent_of_prediction	percent_of_DWPC	metapath
Decamethonium—CHRNE—pituitary gland—Graves' disease	0.213	0.272	CbGeAlD
Decamethonium—CHRNG—adipose tissue—Graves' disease	0.106	0.135	CbGeAlD
Decamethonium—CHRNB1—eye—Graves' disease	0.0733	0.0934	CbGeAlD
Decamethonium—CHRND—thyroid gland—Graves' disease	0.0728	0.0928	CbGeAlD
Decamethonium—CHRNA1—thyroid gland—Graves' disease	0.0608	0.0774	CbGeAlD
Decamethonium—CHRNB1—adipose tissue—Graves' disease	0.0542	0.0691	CbGeAlD
Decamethonium—CHRNA2—thyroid gland—Graves' disease	0.0504	0.0643	CbGeAlD
Decamethonium—CHRNB1—thyroid gland—Graves' disease	0.0469	0.0598	CbGeAlD
Decamethonium—ACHE—thyroid gland—Graves' disease	0.0407	0.0518	CbGeAlD
Decamethonium—BCHE—pituitary gland—Graves' disease	0.0232	0.0296	CbGeAlD
Decamethonium—BCHE—adipose tissue—Graves' disease	0.0231	0.0294	CbGeAlD
Decamethonium—BCHE—thyroid gland—Graves' disease	0.02	0.0255	CbGeAlD
Decamethonium—HRH3—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.018	0.0836	CbGpPWpGaD
Decamethonium—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.0159	0.0738	CbGpPWpGaD
Decamethonium—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.015	0.0694	CbGpPWpGaD
Decamethonium—CHRNG—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.012	0.0555	CbGpPWpGaD
Decamethonium—CHRNE—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.0112	0.0522	CbGpPWpGaD
Decamethonium—CHRNG—Neuronal System—GABRA3—Graves' disease	0.00917	0.0425	CbGpPWpGaD
Decamethonium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00885	0.0411	CbGpPWpGaD
Decamethonium—CHRNE—Neuronal System—GABRA3—Graves' disease	0.00862	0.04	CbGpPWpGaD
Decamethonium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00753	0.0349	CbGpPWpGaD
Decamethonium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00715	0.0332	CbGpPWpGaD
Decamethonium—CHRND—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00665	0.0309	CbGpPWpGaD
Decamethonium—HRH3—Monoamine Transport—IL1B—Graves' disease	0.00591	0.0274	CbGpPWpGaD
Decamethonium—CHRM2—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00586	0.0272	CbGpPWpGaD
Decamethonium—CHRNA1—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00566	0.0263	CbGpPWpGaD
Decamethonium—CHRNA2—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00538	0.0249	CbGpPWpGaD
Decamethonium—CHRND—Neuronal System—GABRA3—Graves' disease	0.0051	0.0237	CbGpPWpGaD
Decamethonium—CHRNA1—Neuronal System—GABRA3—Graves' disease	0.00434	0.0201	CbGpPWpGaD
Decamethonium—HRH3—Monoamine Transport—TNF—Graves' disease	0.00429	0.0199	CbGpPWpGaD
Decamethonium—CHRNA2—Neuronal System—GABRA3—Graves' disease	0.00412	0.0191	CbGpPWpGaD
Decamethonium—ACHE—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00333	0.0154	CbGpPWpGaD
Decamethonium—HRH3—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00328	0.0152	CbGpPWpGaD
Decamethonium—BCHE—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00297	0.0138	CbGpPWpGaD
Decamethonium—ACHE—Monoamine Transport—IL1B—Graves' disease	0.00283	0.0131	CbGpPWpGaD
Decamethonium—HRH3—G alpha (i) signalling events—CXCL10—Graves' disease	0.00267	0.0124	CbGpPWpGaD
Decamethonium—ACHE—Neuronal System—GABRA3—Graves' disease	0.00255	0.0118	CbGpPWpGaD
Decamethonium—HRH3—GPCR ligand binding—TSHR—Graves' disease	0.0025	0.0116	CbGpPWpGaD
Decamethonium—BCHE—Neuronal System—GABRA3—Graves' disease	0.00227	0.0105	CbGpPWpGaD
Decamethonium—HRH3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00212	0.00984	CbGpPWpGaD
Decamethonium—ACHE—Monoamine Transport—TNF—Graves' disease	0.00205	0.00952	CbGpPWpGaD
Decamethonium—ACHE—ATF-2 transcription factor network—IFNG—Graves' disease	0.00194	0.00902	CbGpPWpGaD
Decamethonium—HRH3—GPCR ligand binding—CXCL10—Graves' disease	0.00161	0.00749	CbGpPWpGaD
Decamethonium—ACHE—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00155	0.00719	CbGpPWpGaD
Decamethonium—HRH3—GPCR downstream signaling—TSHR—Graves' disease	0.00141	0.00655	CbGpPWpGaD
Decamethonium—BCHE—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00138	0.00641	CbGpPWpGaD
Decamethonium—HRH3—Signaling by GPCR—TSHR—Graves' disease	0.00128	0.00595	CbGpPWpGaD
Decamethonium—ACHE—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.0012	0.00557	CbGpPWpGaD
Decamethonium—ACHE—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.00116	0.00537	CbGpPWpGaD
Decamethonium—CHRM2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00107	0.00495	CbGpPWpGaD
Decamethonium—ACHE—Metabolism of proteins—B3GNT2—Graves' disease	0.00101	0.00471	CbGpPWpGaD
Decamethonium—HRH3—GPCR downstream signaling—CXCL10—Graves' disease	0.000912	0.00423	CbGpPWpGaD
Decamethonium—BCHE—Metabolism of proteins—B3GNT2—Graves' disease	0.000905	0.0042	CbGpPWpGaD
Decamethonium—CHRM2—G alpha (i) signalling events—CXCL10—Graves' disease	0.000867	0.00402	CbGpPWpGaD
Decamethonium—HRH3—Signaling by GPCR—CXCL10—Graves' disease	0.000828	0.00384	CbGpPWpGaD
Decamethonium—CHRM2—GPCR ligand binding—TSHR—Graves' disease	0.000812	0.00377	CbGpPWpGaD
Decamethonium—HRH3—Signaling Pathways—TSHR—Graves' disease	0.000757	0.00351	CbGpPWpGaD
Decamethonium—HRH3—GPCR downstream signaling—IL2RA—Graves' disease	0.000697	0.00324	CbGpPWpGaD
Decamethonium—ACHE—Metabolism—GC—Graves' disease	0.00069	0.0032	CbGpPWpGaD
Decamethonium—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000689	0.0032	CbGpPWpGaD
Decamethonium—HRH3—Signaling by GPCR—IL2RA—Graves' disease	0.000633	0.00294	CbGpPWpGaD
Decamethonium—BCHE—Metabolism—GC—Graves' disease	0.000616	0.00286	CbGpPWpGaD
Decamethonium—CHRM2—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000541	0.00251	CbGpPWpGaD
Decamethonium—CHRM2—GPCR ligand binding—CXCL10—Graves' disease	0.000525	0.00243	CbGpPWpGaD
Decamethonium—ACHE—Metabolism—B3GNT2—Graves' disease	0.000523	0.00243	CbGpPWpGaD
Decamethonium—ACHE—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000491	0.00228	CbGpPWpGaD
Decamethonium—HRH3—Signaling Pathways—CXCL10—Graves' disease	0.000489	0.00227	CbGpPWpGaD
Decamethonium—BCHE—Metabolism—B3GNT2—Graves' disease	0.000467	0.00217	CbGpPWpGaD
Decamethonium—CHRM2—GPCR downstream signaling—TSHR—Graves' disease	0.000459	0.00213	CbGpPWpGaD
Decamethonium—CHRM2—Signaling by GPCR—TSHR—Graves' disease	0.000417	0.00193	CbGpPWpGaD
Decamethonium—CHRM2—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000393	0.00182	CbGpPWpGaD
Decamethonium—HRH3—Signaling Pathways—IL2RA—Graves' disease	0.000374	0.00174	CbGpPWpGaD
Decamethonium—CHRM2—GPCR downstream signaling—CXCL10—Graves' disease	0.000297	0.00138	CbGpPWpGaD
Decamethonium—CHRM2—Signaling by GPCR—CXCL10—Graves' disease	0.000269	0.00125	CbGpPWpGaD
Decamethonium—CHRM2—Signaling Pathways—TSHR—Graves' disease	0.000246	0.00114	CbGpPWpGaD
Decamethonium—CHRM2—GPCR downstream signaling—IL2RA—Graves' disease	0.000227	0.00105	CbGpPWpGaD
Decamethonium—CHRM2—Signaling by GPCR—IL2RA—Graves' disease	0.000206	0.000955	CbGpPWpGaD
Decamethonium—CHRM2—Signaling Pathways—CXCL10—Graves' disease	0.000159	0.000738	CbGpPWpGaD
Decamethonium—CHRM2—Signaling Pathways—IL2RA—Graves' disease	0.000122	0.000564	CbGpPWpGaD
